Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base

Jacob, John Doromal; Hodge, Caitlin; Franko, Jan; Pezzi, Christopher M.; Goldman, Charles D.; Klimberg, V. Suzanne

doi:10.1002/jso.24241

Cited by 38 publications

(75 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most cases of secretory carcinoma lack or weakly express oestrogen receptor (ER) and progesterone receptor (PR). Secretory carcinoma has also been shown to lack human epidermal growth factor receptor 2 (HER2) overexpression and HER2 gene amplification . Despite this triple‐negative immunophenotype, the clinical course of secretory carcinoma is typically indolent.…”

Section: Introductionmentioning

confidence: 99%

“…These lethal cases were mainly reported in older patients; however, two cases were initially diagnosed in adolescent patients, who ultimately succumbed to their disease in their 20s. Given the paucity of cases, consensus on optimal management of secretory carcinoma has remained elusive . Although surgical excision has been curative in most patients, chemotherapy and radiation therapy have been utilised in clinically aggressive cases.…”

Section: Introductionmentioning

confidence: 99%

“…Secretory carcinoma has also been shown to lack human epidermal growth factor receptor 2 (HER2) overexpression and HER2 gene amplification. 4 Despite this triple-negative immunophenotype, the clinical course of secretory carcinoma is typically indolent. The presence of axillary lymph node metastasis has been reported in up to 30% of cases.…”

Section: Introductionmentioning

confidence: 99%

“…Given the paucity of cases, consensus on optimal management of secretory carcinoma has remained elusive. 4,20 Although surgical excision has been curative in most patients, chemotherapy and radiation therapy have been utilised in clinically aggressive cases.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential

et al. 2019

View full text Add to dashboard Cite

Aims Secretory carcinoma of the breast (SCB) is a rare histological type of breast carcinoma with a generally indolent clinical behaviour. We aim to elucidate the clinical, pathological and molecular findings of SCB cases and identify characteristics associated with aggressive clinical courses. Methods and results Fourteen patients with SCB were identified, including 12 women and two men, with a median age of 56 years (range = 8–81 years). Clinical data, histological diagnosis, molecular findings and follow‐up were reviewed. Eight patients presented with palpable masses and four patients with radiographic abnormalities. All cases were unilateral. Surgical procedures included excisional biopsies and ipsilateral mastectomies. In 10 cases, oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) results were obtained, with six cases positive for ER and three positive for PR. All cases lacked HER2 overexpression. Sentinel lymph node biopsy was performed in 10 cases, and two patients had axillary lymph node metastasis. Follow‐up ranged from 21 to 212 months (median = 70 months). Two patients developed distant metastasis of SCB. Molecular analysis of these aggressive tumours revealed amplification of the 16p13.3 locus, a TERT promotor mutation and loss of 9p21.3 locus. Review of the literature for SCB cases with distant metastasis was performed. Conclusions Although SCBs are generally associated with a favourable prognosis, our study and review demonstrate that a subset of SCBs may develop distant metastases. Further studies are warranted to identify markers predictive of more aggressive clinical behaviour in this rare breast cancer subtype.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Secretory carcinoma is a rare tumor with frequency less than 0.15% of all breast cancers.Mean age in a study was found to be 25 years with female predominance [4]. However a recent study conducted on 246 invasive secretory carcinomas showed mean age of 56.4 years [5]. This goes against the previous view that it is found predominantly in children.…”

Section: Discussionmentioning

confidence: 78%

Lung metastasis in secretory carcinoma breast –Rare presention

Mirza

Fatima

Haider

2018

Trop J Pathol Microbiol

View full text Add to dashboard Cite

Secretory carcinoma is a rare breast cancer with mean age of 25 years. It was initially thought to be a tumour of children but can also occur in adults and old age. Tumour cells are cytologically bland and form glands and microcystic spaces containing abundant secretion. They are triple negative tumours but with good prognosis and excellent response to surgery. However, the patients should be kept on long term follow up as late occurrence of metastasis isknown. Here we report a patient with diagnosis of Secretory carcinoma breast who developed lung metastasis four years later.

show abstract

Integrated Multi‐Omic Analyses Support Distinguishing Secretory Carcinoma of the Breast from Basal‐Like Triple‐Negative Breast Cancer

Jin

Lee

Woo

et al. 2018

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base

Abstract: SBC is an uncommon tumor that is often well-differentiated and seen in younger women. Contrary to prior reports, they are frequently hormone receptor-positive. Compared to IDC, overall survival is improved. J. Surg. Oncol. 2016;113:721-725. © 2016 Wiley Periodicals, Inc.

Cited by 38 publications

References 32 publications

Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential

Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential

Lung metastasis in secretory carcinoma breast –Rare presention

Integrated Multi‐Omic Analyses Support Distinguishing Secretory Carcinoma of the Breast from Basal‐Like Triple‐Negative Breast Cancer

Contact Info

Product

Resources

About